SG11202008030WA - Kv7 channel activators compositions and methods of use - Google Patents
Kv7 channel activators compositions and methods of useInfo
- Publication number
- SG11202008030WA SG11202008030WA SG11202008030WA SG11202008030WA SG11202008030WA SG 11202008030W A SG11202008030W A SG 11202008030WA SG 11202008030W A SG11202008030W A SG 11202008030WA SG 11202008030W A SG11202008030W A SG 11202008030WA SG 11202008030W A SG11202008030W A SG 11202008030WA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- channel activators
- compositions
- activators compositions
- channel
- Prior art date
Links
- 239000012190 activator Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862644902P | 2018-03-19 | 2018-03-19 | |
US201862644932P | 2018-03-19 | 2018-03-19 | |
US201862663438P | 2018-04-27 | 2018-04-27 | |
US201862697198P | 2018-07-12 | 2018-07-12 | |
PCT/US2019/023039 WO2019183148A1 (en) | 2018-03-19 | 2019-03-19 | Kv7 channel activators compositions and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008030WA true SG11202008030WA (en) | 2020-10-29 |
Family
ID=67905138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008030WA SG11202008030WA (en) | 2018-03-19 | 2019-03-19 | Kv7 channel activators compositions and methods of use |
Country Status (13)
Country | Link |
---|---|
US (4) | US10851067B2 (en) |
EP (1) | EP3768677A4 (en) |
JP (2) | JP2021518844A (en) |
KR (1) | KR20200133259A (en) |
CN (1) | CN112771039A (en) |
AU (3) | AU2019239955B2 (en) |
BR (1) | BR112020018933A2 (en) |
CA (1) | CA3093976A1 (en) |
IL (2) | IL310136A (en) |
MX (2) | MX2020009693A (en) |
NZ (1) | NZ767228A (en) |
SG (1) | SG11202008030WA (en) |
WO (1) | WO2019183148A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9481653B2 (en) * | 2014-09-12 | 2016-11-01 | Knopp Biosciences Llc | Benzoimidazol-1,2-yl amides as Kv7 channel activators |
WO2019183148A1 (en) * | 2018-03-19 | 2019-09-26 | Knopp Biosciences Llc | Kv7 channel activators compositions and methods of use |
WO2021055538A1 (en) * | 2019-09-17 | 2021-03-25 | Knopp Biosciences Llc | Methods of use for kv7 channel activators |
WO2024050389A1 (en) * | 2022-08-30 | 2024-03-07 | Biohaven Therapeutics Ltd. | Combination therapies including metal channel activators and nmda receptor antagonists |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0772181B2 (en) | 1989-06-26 | 1995-08-02 | 株式会社大塚製薬工場 | Benzimidazole derivative |
JPH0772181A (en) | 1993-09-03 | 1995-03-17 | Advantest Corp | Potential waveform measurement method and device |
GB9413724D0 (en) | 1994-07-07 | 1994-08-24 | Wellcome Found | Therapeutic nucleosides |
US6855714B2 (en) | 2001-07-06 | 2005-02-15 | Schering Aktiengesellschaft | 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives |
SE0301701D0 (en) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
AR054045A1 (en) * | 2005-05-18 | 2007-05-30 | Neuraxon Inc | BENZOIMIDAZOL COMPOUNDS REPLACED WITH NON-INHIBITORY DUAL ACTIVITY AND MU AGIOIST OPIOID |
CN101516873A (en) * | 2006-10-03 | 2009-08-26 | 神经研究公司 | Indazolyl derivatives useful as potassium channel modulating agents |
CN101778833A (en) | 2007-08-10 | 2010-07-14 | 日本曹达株式会社 | Nitrogen-containing heterocyclic compound and pest control agent |
DK2409975T3 (en) | 2007-11-22 | 2015-08-03 | Zenyaku Kogyo Kk | Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound |
GB0723794D0 (en) | 2007-12-05 | 2008-01-16 | Lectus Therapeutics Ltd | Potassium ion channel modulators and uses thereof |
EP2231661A1 (en) | 2007-12-19 | 2010-09-29 | Amgen, Inc. | Inhibitors of pi3 kinase |
WO2010051819A1 (en) | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
EP2373163B1 (en) | 2008-12-19 | 2015-06-10 | Genentech, Inc. | Heterocyclic compounds and methods of use |
AU2011275393B2 (en) | 2010-07-08 | 2014-04-10 | Pfizer Inc. | Piperidinyl pyrimidine amides as Kv7 potassium channel openers |
MX2013001313A (en) | 2010-08-05 | 2013-06-13 | Amgen Inc | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase. |
ES2885424T3 (en) * | 2013-03-15 | 2021-12-13 | Knopp Biosciences Llc | Imidazo (4,5-B) pyridin-2-yl amides as activators of the Kv7 channel |
WO2015023958A1 (en) * | 2013-08-15 | 2015-02-19 | The University Of Kansas | Toll-like receptor agonists |
US9481653B2 (en) | 2014-09-12 | 2016-11-01 | Knopp Biosciences Llc | Benzoimidazol-1,2-yl amides as Kv7 channel activators |
WO2019183148A1 (en) * | 2018-03-19 | 2019-09-26 | Knopp Biosciences Llc | Kv7 channel activators compositions and methods of use |
-
2019
- 2019-03-19 WO PCT/US2019/023039 patent/WO2019183148A1/en active Application Filing
- 2019-03-19 SG SG11202008030WA patent/SG11202008030WA/en unknown
- 2019-03-19 CN CN201980033266.7A patent/CN112771039A/en active Pending
- 2019-03-19 EP EP19772264.8A patent/EP3768677A4/en active Pending
- 2019-03-19 NZ NZ767228A patent/NZ767228A/en unknown
- 2019-03-19 BR BR112020018933-2A patent/BR112020018933A2/en unknown
- 2019-03-19 KR KR1020207029659A patent/KR20200133259A/en not_active Application Discontinuation
- 2019-03-19 MX MX2020009693A patent/MX2020009693A/en unknown
- 2019-03-19 IL IL310136A patent/IL310136A/en unknown
- 2019-03-19 IL IL277419A patent/IL277419B1/en unknown
- 2019-03-19 US US16/358,642 patent/US10851067B2/en active Active
- 2019-03-19 AU AU2019239955A patent/AU2019239955B2/en active Active
- 2019-03-19 CA CA3093976A patent/CA3093976A1/en active Pending
- 2019-03-19 JP JP2020551340A patent/JP2021518844A/en active Pending
-
2020
- 2020-09-17 MX MX2023001153A patent/MX2023001153A/en unknown
- 2020-10-22 US US17/077,068 patent/US11261162B2/en active Active
-
2022
- 2022-01-07 US US17/570,536 patent/US11724990B2/en active Active
-
2023
- 2023-06-20 US US18/338,096 patent/US20240002349A1/en active Pending
- 2023-11-16 JP JP2023195267A patent/JP2024026104A/en active Pending
- 2023-11-17 AU AU2023266373A patent/AU2023266373B2/en active Active
-
2024
- 2024-04-17 AU AU2024202496A patent/AU2024202496A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2019239955B2 (en) | 2023-08-24 |
MX2023001153A (en) | 2023-02-22 |
EP3768677A4 (en) | 2021-12-22 |
US20190284142A1 (en) | 2019-09-19 |
US11724990B2 (en) | 2023-08-15 |
AU2019239955A1 (en) | 2020-10-01 |
NZ767228A (en) | 2023-11-24 |
US10851067B2 (en) | 2020-12-01 |
IL277419A (en) | 2020-11-30 |
CN112771039A (en) | 2021-05-07 |
US20230000831A1 (en) | 2023-01-05 |
CA3093976A1 (en) | 2019-09-26 |
AU2023266373A1 (en) | 2023-12-07 |
IL277419B1 (en) | 2024-03-01 |
JP2021518844A (en) | 2021-08-05 |
MX2020009693A (en) | 2021-01-08 |
KR20200133259A (en) | 2020-11-26 |
BR112020018933A2 (en) | 2020-12-29 |
AU2023266373B2 (en) | 2024-02-08 |
WO2019183148A1 (en) | 2019-09-26 |
US20210130299A1 (en) | 2021-05-06 |
AU2024202496A1 (en) | 2024-05-09 |
EP3768677A1 (en) | 2021-01-27 |
US11261162B2 (en) | 2022-03-01 |
IL310136A (en) | 2024-03-01 |
US20240002349A1 (en) | 2024-01-04 |
JP2024026104A (en) | 2024-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2582482B (en) | CASZ compositions and methods of use | |
IL280963A (en) | Anti-gdf15 antibodies, compositions and methods of use | |
GB2582100B (en) | CAS12C Compositions and methods of use | |
IL277419A (en) | Kv7 channel activators compositions and methods of use | |
EP3576782A4 (en) | Construct-peptide compositions and methods of use thereof | |
ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
IL276135A (en) | Compositions and methods of use | |
ZA201906169B (en) | Synthekine compositions and methods of use | |
SG11202106585UA (en) | Polishing compositions and methods of using same | |
GB202105087D0 (en) | Microbial compositions and methods of use | |
SG11202106584QA (en) | Polishing compositions and methods of using same | |
SG11202011274YA (en) | Chemical compositions and methods of using same | |
SG11202111672RA (en) | Cancer associated antibody compositions and methods of use | |
SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
IL283782A (en) | Anellosomes and methods of use | |
IL280000A (en) | Tumor reduction formulations and methods of use thereof | |
ZA202000502B (en) | Cosmetic compositions and methods of use | |
EP3843555A4 (en) | Anthocyanin-based colorant compositions and methods of use thereof | |
GB2589398B (en) | Compounds and methods of use | |
EP4081233A4 (en) | Composition and methods of manufacture | |
ZA202007107B (en) | Compositions comprising pcsk9-binding molecules and methods of use | |
SG11202012283XA (en) | Additive composition and method of preparing the same | |
SG11202011121UA (en) | Dantrolene formulations and methods of their use | |
SG11202002351SA (en) | Poloxamer compositions and methods of making and using same | |
IL291318A (en) | Methods of use for kv7 channel activators |